January 29, 2021
PAR-20-316 - NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)
National Institute of Allergy and Infectious Diseases (NIAID)
This Notice informs potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective immediately, in PAR-20-316 "NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)".
The following text has been added to reflect NIAID's participation in this FOA:
Part 1. Overview Information
Components of Participating Organizations
National Institute of Allergy and Infectious Diseases (NIAID)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.855
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
The Chemical Countermeasures Research Program (CCRP) at the NIAID is responsible for the oversight and overall execution of the medical chemical countermeasures against chemical threats initiative across the NIH. To learn more about the CCRP and the NIAID leadership role, see DOI: 10.1002/ddr.21707.
Section VII. Agency Contacts
Scientific/Research Contact(s)
Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: dy70v@nih.gov
Financial/Grants Management Contact(s)
Jason Lundgren
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (240) 669-2973
Email: Jason.Lundgren@nih.gov
All other aspects of the FOA remain the same.
Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: dy70v@nih.gov